

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

NOVO NORDISK INC. and NOVO
NORDISK A/S

Plaintiff(s),

v.

MYLAN PHARMACEUTICALS INC.

Defendant(s)/
Third-Party Plaintiff(s),

v.

Third-Party Defendant(s).

Civil Action No. 1:22-cv-23

DISCLOSURE STATEMENT PURSUANT TO Fed. R. Civ. P. 7.1
(Civil Action)

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, **Plaintiffs**,
(type of party)
who is **Novo Nordisk A/S and Novo Nordisk Inc.**, makes the following disclosure:
(name of party)

1. Is the party a non-governmental corporate party?

YES NO

2. If the answer to Number 1 is “yes,” list below any parent corporation or state that there is no such corporation:

Novo Nordisk A/S ("NNAS") is a publicly traded Danish corporation. NNAS's corporate parent is Novo A/S.

Novo Nordisk Inc. is a privately held corporation wholly owned by Novo Nordisk US Holdings, Inc. Novo Nordisk US Holdings, Inc. is a privately held corporation wholly owned by NNAS.

3. If the answer to Number 1 is “yes,” list below any publically-held corporation that owns 10% or more of the party’s stock or state that there is no such corporation:

No publicly held company owns 10% or more of the stock of NNAS or Novo Nordisk Inc.

The undersigned party understands that under Rule 7.1 of the Federal Rules of Civil Procedure, it will promptly file a supplemental statement upon any change in the information that this statement requires.

/s/ James F. Companion

Signature of Counsel for Party

Date: March 18, 2022